Who Gains Most? A 10-Year Experience With 611 Thoracoscopic Talc Pleurodeses

Annals of Thoracic Surgery

Volumn 83, Issue 6, 2007, Pages 1940-1945

  Steger, Volker ^a   Mika, Ute ^a   Toomes, Heikki ^a   Walker, Tobias ^b   Engel, Corinna ^c   Kyriss, Thomas ^a   Ziemer, Gerhard ^b   Friedel, Godehard ^a  

^a Schillerhoehe Hospital   (Germany)

^b Department of Thoracic Cardiac and Vascular Surgery ^*  (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BODY MASS; CHILD; DEATH; DRAIN; FEMALE; FOLLOW UP; GENDER; GENERAL CONDITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IRRADIATION; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; PLEURODESIS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SYMPTOM; THORACOSCOPIC TALC PLEURODESIS; THORAX; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; PLEURAL EFFUSION; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; RETROSPECTIVE STUDIES; SCLEROSING SOLUTIONS; SURVIVAL ANALYSIS; TALC; THORACOSCOPY;

EID: 34249022013     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2007.02.061     Document Type: Article

References (45)

1. Diacon A.H., Wyser C., Bolliger C.T., et al. Prospective randomized comparison of thoracoscopic talc poudrage under local anesthesia versus bleomycin instillation for pleurodesis in malignant pleural effusions. Am J Respir Crit Care Med 162 (2000) 1445-1449
2. Bresticker M.A., Oba J., LoCicero III J., and Greene R. Optimal pleurodesis: a comparison study. Ann Thorac Surg 55 (1993) 364-366
3. Colt H.G., Russack V., Chiu Y., et al. A comparison of thoracoscopic talc insufflation, slurry, and mechanical abrasion pleurodesis. Chest 111 (1997) 442-448
4. Zimmer P.W., Hill M., Casey K., Harvey E., and Low D.E. Prospective randomized trial of talc slurry vs bleomycin in pleurodesis for symptomatic malignant pleural effusions. Chest 112 (1997) 430-434
5. Karnofsky D.A., Abelmann W.H., Craver L.F., and Burchenal J.H. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. Cancer 1 (1948) 634-656
6. Saffran L., Ost D.E., Fein A.M., and Schiff M.J. Outpatient pleurodesis of malignant pleural effusions using a small-bore pigtail catheter. Chest 118 (2000) 417-421
7. Marom E.M., Patz Jr. E.F., Erasmus J.J., McAdams H.P., Goodman P.C., and Herndon J.E. Malignant pleural effusions: treatment with small-bore-catheter thoracostomy and talc pleurodesis. Radiology 210 (1999) 277-281
8. Waller D.A., Morritt G.N., and Forty J. Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion. Chest 107 (1995) 1454-1456
9. Su W.C., Lai W.W., Chen H.H., et al. Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion. A pilot study. Oncology 64 (2003) 18-24
10. Haddad F.J., Younes R.N., Gross J.L., and Deheinzelin D. Pleurodesis in patients with malignant pleural effusions: talc slurry or bleomycin? Results of a prospective randomized trial. World J Surg 28 (2004) 749-753
11. Waller D.A. The role of surgery in diagnosis and treatment of malignant pleural mesothelioma. Curr Opin Oncol 15 (2003) 139-143
12. Sartori S., Tassinari D., Ceccotti P., et al. Prospective randomized trial of intrapleural bleomycin versus interferon alfa-2b via ultrasound-guided small-bore chest tube in the palliative treatment of malignant pleural effusions. J Clin Oncol 22 (2004) 1228-1233
13. Cheng D.S., Rogers J., Wheeler A., Parker R., Teixeira L., and Light R.W. The effects of intrapleural polyclonal anti-tumor necrosis factor alpha (TNF alpha) Fab fragments on pleurodesis in rabbits. Lung 178 (2000) 19-29
14. Lee Y.C., Yasay J.R., Johnson J.E., et al. Comparing transforming growth factor-beta2, talc and bleomycin as pleurodesing agents in sheep. Respirology 7 (2002) 209-216
15. Bethune N. Pleural poudrage. J Thoracic Surgery 4.1935 (1934) 251-261
16. Baumann M.H., Heinrich K., Sahn S.A., and Strange C. Pleural macrophages differentially alter mesothelial cell growth and collagen production. Inflammation 17 (1993) 1-12
17. Kroegel C., and Antony V.B. Immunobiology of pleural inflammation: potential implications for pathogenesis, diagnosis and therapy. Eur Respir J 10 (1997) 2411-2418
18. Marchi E., Vargas F.S., Acencio M.M., Antonangelo L., Genofre E.H., and Teixeira L.R. Evidence that mesothelial cells regulate the acute inflammatory response in talc pleurodesis. Eur Respir J 28 (2006) 929-932
19. Chambers J.S. Palliative treatment of neoplastic pleural effusion with intercostal intubation and talc instillation. West J Surg Obstet Gynecol 66 (1958) 26-28
20. Erickson K.V., Yost M., Bynoe R., Almond C., and Nottingham J. Primary treatment of malignant pleural effusions: video-assisted thoracoscopic surgery poudrage versus tube thoracostomy. Am Surg 68 (2002) 955-959
21. Hartman D.L., Gaither J.M., Kesler K.A., Mylet D.M., Brown J.W., and Mathur P.N. Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg 105 (1993) 743-747
22. Shaw P., and Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev (2004) CD002916
23. Tan C., Sedrakyan A., Browne J., Swift S., and Treasure T. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg 29 (2006) 829-838
24. Putnam Jr. J.B., Light R.W., Rodriguez R.M., et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 86 (1999) 1992-1999
25. Banerjee A.K., Willetts I., Robertson J.F., and Blamey R.W. Pleural effusion in breast cancer: a review of the Nottingham experience. Eur J Surg Oncol 20 (1994) 33-36
26. Clementsen P., Evald T., Grode G., Hansen M., Krag Jacobsen G., and Faurschou P. Treatment of malignant pleural effusion: pleurodesis using a small percutaneous catheter. A prospective randomized study. Respir Med 92 (1998) 593-596
27. Evans T.R., Stein R.C., Pepper J.R., Gazet J.C., Ford H.T., and Coombes R.C. A randomised prospective trial of surgical against medical tetracycline pleurodesis in the management of malignant pleural effusions secondary to breast cancer. Eur J Cancer 29A (1993) 316-319
28. Gravelyn T.R., Michelson M.K., Gross B.H., and Sitrin R.G. Tetracycline pleurodesis for malignant pleural effusions. A 10-year retrospective study. Cancer 59 (1987) 1973-1977
29. Heffner J.E., Standerfer R.J., Torstveit J., and Unruh L. Clinical efficacy of doxycycline for pleurodesis. Chest 105 (1994) 1743-1747
30. Herrington J.D., Gora-Harper M.L., and Salley R.K. Chemical pleurodesis with doxycycline 1 g. Pharmacotherapy 16 (1996) 280-285
31. Hsu W.H., Chiang C.D., Chen C.Y., Kwan P.C., and Hsu J.Y. Ultrasound-guided small-bore Elecath tube insertion for the rapid sclerotherapy of malignant pleural effusion. Jpn J Clin Oncol 28 (1998) 187-191
32. Sahn S.A. Management of malignant pleural effusions. Monaldi Arch Chest Dis 56 (2001) 394-399
33. Arapis K., Caliandro R., Stern J.B., Girard P., Debrosse D., and Gossot D. Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients. Surg Endosc 20 (2006) 919-923
34. de Campos J.R., Vargas F.S., Campos-Werebe E., et al. Thoracoscopy talc poudrage: a 15-year experience. Chest 119 (2001) 801-806
35. Petrou M., Kaplan D., and Goldstraw P. Management of recurrent malignant pleural effusions. The complementary role talc pleurodesis and pleuroperitoneal shunting. Cancer 75 (1995) 801-805
36. Bal S., and Hasan S.S. Thoracoscopic management of malignant pleural effusion. Int Surg 78 (1993) 324-327
37. Burrows C.M., Mathews W.C., and Colt H.G. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest 117 (2000) 73-78
38. Aelony Y., Yao J.F., and King R.R. Prognostic value of pleural fluid pH in malignant epithelial mesothelioma after talc poudrage. Respiration 73 (2006) 334-339
39. Dresler C.M., Olak J., Herndon J.E., et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 127 (2005) 909-915
40. Kilic D., Akay H., Kavukcu S., et al. Management of recurrent malignant pleural effusion with chemical pleurodesis. Surg Today 35 (2005) 634-638
41. Agarwal R., Aggarwal A.N., Gupta D., and Jindal S.K. Efficacy and safety of iodopovidone in chemical pleurodesis: a meta-analysis of observational studies. Respir Med 100 (2006) 2043-2047
42. Akopov A.L., Egorov V.I., Varlamov V.V., Levashev Y.N., and Artioukh D.Y. Thoracoscopic collagen pleurodesis in the treatment of malignant pleural effusions. Eur J Cardiothorac Surg 28 (2005) 750-753
43. Kuzdzal J., Sladek K., Wasowski D., et al. Talc powder vs doxycycline in the control of malignant pleural effusion: a prospective, randomized trial. Med Sci Monit 9 (2003) I54-I59
44. Apffelstaedt J.P., Van Zyl J.A., and Muller A.G. Breast cancer complicated by pleural effusion: patient characteristics and results of surgical management. J Surg Oncol 58 (1995) 173-175
45. Arora V.K., Varma R., and Reddy K.S. Radiation: an alternative agent for pleurodesis. Indian J Chest Dis Allied Sci 35 (1993) 59-61